Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Bio-Rad Laboratories, Inc./ 10-Q

Quarterly Report · 10-Q

Bio-Rad Laboratories, Inc.

Quarterly Report

Filed Aug 4, 2026Accepted Aug 4, 2026, 4:20 PM EDTCIK 12208Accession 0000012208-26-000048
View company →Permanent SEC source ↗
Share

Company context

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO. B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,100 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com

Current securities

BIONYSE · EQUITY · CurrentBIO BNYSE · EQUITY · Current

Recent company filings

  1. 10-Q filingNov 4, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
  3. 4 filingSep 3, 2026
  4. Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Regulation FD DisclosureAug 4, 2026
  5. 144 filingMay 28, 2026

Registered securities in this filing

BIO-RAD LABORATORIES, INC. · 10-Q · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Class A Common Stock, Par Value $0.0001 per share

Symbol
BIO
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Class B Common Stock, Par Value $0.0001 per share

Symbol
BIO.B
Exchange
NYSE
Classification
COMMON
Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000001220826000048 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.